Maguire R T, Pascucci V L, Maroli A N, Gulfo J V
Cytogen Corporation, Princeton, NJ 08540.
Cancer. 1993 Dec 1;72(11 Suppl):3453-62. doi: 10.1002/1097-0142(19931201)72:11+<3453::aid-cncr2820721612>3.0.co;2-#.
Application of monoclonal antibody (MoAb) technology to cancer management is discussed by reviewing the development and clinical evaluation of two MoAb-based immunoscintigraphic agents (111In-satumomab pendetide [OncoScint CR/OV-In] and 111In-CYT-356; Cytogen Corporation, Princeton, NJ). Both agents were prepared using a site-specific MoAb modification method that preserves the immunoreactivity of the radiolabeled immunoconjugate. 111In-satumomab pendetide is an 111In-labeled conjugate of the murine MoAb B72.3, which is directed to TAG-72, an antigen expressed by the majority of adenocarcinomas. By providing information that complements the results of standard radiographic diagnostic modalities, this imaging agent can aid in the treatment of patients with colorectal or ovarian cancer. Immunoscintigraphy with 111In-satumomab pendetide has been shown to assist in medical-surgical management by detecting occult extrahepatic lesions, clarifying equivocal results of other diagnostic imaging tests, and evaluating the extent and resectability of known tumor lesions. 111In-CYT-356 is an 111In-labeled conjugate of the murine MoAb 7E11-C5.3, which is reactive with prostatic carcinoma, benign prostatic hypertrophy, and, to a lesser extent, normal prostatic tissue. Results of preliminary clinical investigations suggest that 111In-CYT-356 immunoscintigraphy can be useful for the presurgical staging of prostatic carcinoma and for the detection of occult distant disease in patients with negative or equivocal results on standard imaging tests. Results with these site-specifically radiolabeled immunconjugates demonstrate the clinical utility of MoAb-based imaging agents in the treatment of patients with solid tumors.
通过回顾两种基于单克隆抗体的免疫闪烁显像剂（111铟-萨妥莫单抗喷地肽[OncoScint CR/OV-In]和111铟-CYT-356；新泽西州普林斯顿的细胞遗传学公司）的研发和临床评估，讨论了单克隆抗体（MoAb）技术在癌症治疗中的应用。这两种显像剂均采用位点特异性单克隆抗体修饰方法制备，该方法可保留放射性标记免疫缀合物的免疫反应性。111铟-萨妥莫单抗喷地肽是鼠源单克隆抗体B72.3的111铟标记缀合物，B72.3针对TAG-72，大多数腺癌表达的一种抗原。通过提供补充标准放射学诊断方法结果的信息，这种显像剂可辅助结直肠癌或卵巢癌患者的治疗。已证明，使用111铟-萨妥莫单抗喷地肽进行免疫闪烁显像可通过检测隐匿性肝外病变、明确其他诊断性影像学检查的模糊结果以及评估已知肿瘤病变的范围和可切除性，辅助内科-外科治疗。111铟-CYT-356是鼠源单克隆抗体7E11-C5.3的111铟标记缀合物，它与前列腺癌、良性前列腺增生反应，在较小程度上也与正常前列腺组织反应。初步临床研究结果表明，111铟-CYT-356免疫闪烁显像可用于前列腺癌的术前分期以及标准影像学检查结果为阴性或模糊的患者隐匿性远处疾病的检测。这些位点特异性放射性标记免疫缀合物的结果证明了基于单克隆抗体的显像剂在实体瘤患者治疗中的临床应用价值。
